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AbstrACt 
Introduction Despite the frequent use of therapies in acute 
bronchitis, the evidence of their benefit is lacking, since only 
a few clinical trials have been published, with low sample 
sizes, poor methodological quality and mainly in children. The 
objective of this study is to compare the effectiveness of three 
symptomatic therapies (dextromethorphan, ipratropium or 
honey) associated with usual care and the usual care in adults 
with acute bronchitis.
Methods and analysis This will be a multicentre, 
pragmatic, parallel group, open randomised trial. Patients 
aged 18 or over with uncomplicated acute bronchitis, 
with cough for less than 3 weeks as the main symptom, 
scoring ≥4 in either daytime or nocturnal cough on a 
7-point Likert scale, will be randomised to one of the 
following four groups: usual care, dextromethorphan 30 mg 
three times a day, ipratropium bromide inhaler 20 µg two 
puffs three times a day or honey 30 mg (a spoonful) three 
times a day, all taken for up to 14 days. The exclusion 
criteria will be pneumonia, criteria for hospital admission, 
pregnancy or lactation, concomitant pulmonary disease, 
associated significant comorbidity, allergy, intolerance or 
contraindication to any of the study drugs or admitted to 
a long-term residence. Sample: 668 patients. The primary 
outcome will be the number of days with moderate-to-
severe cough. All patients will be given a paper-based 
symptom diary to be self-administered. A second visit will 
be scheduled at day 2 or 3 for assessing evolution, with 
two more visits at days 15 and 29 for clinical assessment, 
evaluation of adverse effects, re-attendance and 
complications. Patients still with symptoms at day 29 will 
be called 6 weeks after the baseline visit.
Ethics and dissemination The study has been approved 
by the Ethical Board of IDIAP Jordi Gol (reference number: 
AC18/002). The findings of this trial will be disseminated 
through research conferences and peer-review journals.
trial registration number NCT03738917; Pre-results.
bACkground
Lower respiratory tract infections are common 
conditions in primary care. These infections 
affect approximately 5% of adults per year, 
and although they occur throughout the year, 
the incidence is higher in the autumn and 
winter.1 The most frequent of these infections 
is acute bronchitis, which is a self-limiting 
infection of the lower airways that is charac-
terised by clinical manifestations of cough 
with or without sputum and the absence of 
symptoms or signs of pneumonia. Other 
symptoms associated with acute bronchitis 
include fatigue, wheezing, headache, myal-
gias, hoarseness and general discomfort.2 As 
there are no specific diagnostic criteria for 
acute bronchitis, the diagnosis is primarily 
clinical and requires thorough assessment for 
differentiation from pneumonia, as well as 
other upper respiratory tract infections such 
as the common cold or sore throat.3 However, 
cough is not the prominent symptom in the 
strengths and limitations of this study
 ► Since this is a pragmatic clinical trial evaluating the 
effectiveness of different symptomatic therapies, 
masking techniques will not be used.
 ► A microbiological study will not be carried out as 
most cases of acute bronchitis have a viral aetiolo-
gy, and sputum samples are not routinely collected 
in the primary care setting.
 ► The main objective as well as some of the second-
ary objectives of the study are based on information 
provided by the patients themselves in the symptom 
diaries. However, clinicians will encourage patients 
to fill them out appropriately and return them at the 
different follow-up visits scheduled.
 ► Since one-quarter of patients with uncomplicat-
ed acute bronchitis still have cough after the first 
month, these patients will be followed and called 
2 weeks later.
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latter infections. Conversely, cough constitutes the most 
prominent manifestation of acute bronchitis and lasts an 
average of 3 weeks, but may persist for more than 1 month 
in 25% of the patients.4 Initially, the cough is non-pro-
ductive, but after about a week there is an increase in 
mucus production, and in the second week, the colour 
of the sputum often changes from grey-white to purulent. 
Despite being a self-limiting condition, most patients with 
acute bronchitis seek medical advice, mainly because of 
bothersome cough.5 
Treatment of acute bronchitis is usually symptomatic 
and is aimed at relieving annoying respiratory symptoms. 
Treatment should include good hand hygiene, increased 
fluid intake, avoidance of smoking and the elimination 
of environmental cough triggers (for instance, dust), 
and the use of vapours, particularly in low-humidity 
environments, mainly if symptoms include nasal stuff-
iness and nasal discharge. Many general practitioners 
(GPs) prescribe antibiotics, despite evidence of little or 
no benefit, since up to 90% of acute bronchitis are of 
viral aetiology, thereby contributing to the emergence of 
bacterial resistance.6
There are many approaches to the treatment of cough, 
including analgesics, non-steroidal anti-inflammatory 
drugs (NSAIDs), expectorants, mucolytics, antihista-
mines, decongestants, as well as antitussives, β2-agonists or 
other bronchodilators, alternative therapies and natural 
treatment.3 In general, these therapies are available as 
over-the-counter medicines in many countries, and their 
use is very widespread, particularly in southern European 
countries. In a recent observational study conducted in 
12 European areas, Catalonia was one of the zones with 
the highest consumption of mucolytics, bronchodilators 
and antitussives.7
According to the guidelines of the European Respi-
ratory Society, acute cough can be treated with dextro-
methorphan or codeine, but mucolytics, antihistamines 
and bronchodilators should not be prescribed in acute 
lower respiratory tract infections.1 The reviews carried 
out so far conclude that the benefit of these therapies 
is lacking. In general, the studies performed had small 
sample sizes and methodological flaws that make their 
comparison difficult.8 It should be considered that over-
the-counter preparations contain different drugs with a 
variety of modes of action that can make them difficult 
to compare.9 Most clinicians recommend the use of 
analgesics to alleviate mainly fever, headache, myalgia 
and chest pain. NSAIDs are also frequently prescribed 
in patients with lower respiratory infections, mainly for 
relieving cough. However, two recent randomised clin-
ical trials have shown that the number of days with cough 
among patients taking NSAIDs is not significantly lower 
than placebo.10 11 Some trials with inhaled corticosteroids 
have also shown a very marginal benefit, but the number 
of patients included in these studies was small.12 The 
clinical efficacy of other symptomatic drugs is also ques-
tionable. For example, trials assessing the effect of expec-
torants and mucolytics have not shown favourable effects 
on cough associated with acute bronchitis.8 Despite 
being widely used, antihistamines have been evaluated 
primarily in the common cold and were not found to be 
beneficial to alleviate the symptoms of cough.13 Studies 
assessing the benefits of Echinacea, Chinese herbs, Pelargo-
nium sidoides, ivy leaf extracts and other herbal treatments 
have obtained contradictory results, mainly in patients 
with common cold, with low quality of evidence and some 
problems related to safety, and therefore, they are not 
recommended in patients with acute bronchitis.14–17
Most studies that have assessed the benefit of antitus-
sives in adults, mainly codeine and dextromethorphan, 
have been performed in patients with acute cough in 
the context of upper airway infections, thus limiting 
the external validity to patients with acute bronchitis. 
The benefit of dextromethorphan in acute bronchitis is 
controversial. A review published by Parvez et al, including 
451 adults, found that a single dose of dextromethorphan 
30 mg reduced the number of cough bouts measured 
with a microphone by between 19% and 36% within the 
first 3 hours compared with placebo,18 but a meta-analysis 
of six studies in adults with upper airway infections found 
that a single dose of dextromethorphan was slightly more 
effective than placebo in terms of intensity, effort and 
latency within the first 3 hours after intake (between 12% 
and 17% more effective), although the clinical relevance 
of this observation is unclear.19 Studies carried out with 
codeine in adults with acute bronchitis have not been 
shown to be beneficial.20 In children, dextromethorphan 
has not proven to be more effective than placebo.21 In 
a Scandinavian study conducted in 50 children followed 
for 3 days, the average cough score was slightly lower than 
placebo, although statistically significant differences were 
not observed between those taking the antitussive and 
those assigned to placebo.22 Despite this, some guide-
lines recommend a short course of antitussives to reduce 
severe cough during acute illness in adults and children 
over the age of six, but evidence related to their effective-
ness remains unclear.23
A non-negligible per cent of patients with acute bron-
chitis present exaggerated bronchial responsiveness, 
which is mainly reported when the infection is caused 
by viruses and atypical germs.24 However, a recent review 
does not support the routine use of β2-adrenergic 
inhalers in patients with acute bronchitis.25 On the other 
hand, in one of the clinical trials included in this review a 
significant improvement in symptom scores was observed 
in adults who received fenoterol 0.2 mg four times a day 
for 7 days when there was bronchial hyper-reactiveness, 
wheezing or a decrease in the forced expiratory volume 
in one second compared with the same group of patients 
who had received placebo. This effect, however, was not 
observed among patients not presenting airflow obstruc-
tion.26 This same effect has been described with inhaled 
anticholinergics, such as ipratropium and tiotropium 
alone or associated with β2-agonists, but these studies 
were primarily conducted in patients with cough due to 
upper airway infections.27 28 The release of acetylcholine 
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in the airways by parasympathetic stimulation could 
trigger hyper-reactiveness and increase mucosal secre-
tion on the walls of the airways, and this might explain 
the possible antitussive properties of inhaled anticholin-
ergic drugs.29 Other drugs such as leukotriene inhibitors 
have not shown to be useful in acute cough.30 Despite all 
these limitations, the guidelines recommend that bron-
chodilators can only be used in patients with bronchial 
hyper-reactiveness, outweighing the adverse effects, such 
as tremors or nervousness, that these drugs can cause.31
In recent years, some studies using honey in children 
have found favourable results on the frequency of cough, 
patient quality of life and the quality of sleep of both 
parents and children. In a recent meta-analysis, including 
six clinical trials and a total of nearly 900 children, honey 
alleviated cough symptoms compared with no treatment 
or diphenhydramine, but was not found to be more 
effective than dextromethorphan. Apart from the limita-
tions of the small sample sizes of these studies, most chil-
dren received active treatment (different types of honey 
depending on the studies) for only one night, and studies 
evaluating their use in adult population are lacking.32 
There is no clear evidence that some types of honey have 
superior antimicrobial properties to others as described 
in some papers.33 34
Therefore, we believe that this clinical trial is justi-
fied, since evidence of the benefit of these treatments in 
adults with acute bronchitis, with cough as a predomi-
nant symptom, is unclear. We prioritise the use of dextro-
methorphan, as this antitussive is recommended by 
clinical guidelines at the usual dose of 15 mg three times 
a day in the adult population, and ipratropium bromide 
inhalers, since the majority of studies carried out so 
far have considered β2-agonists, with very poor results 
on effectiveness, and the fact that anticholinergics are 
frequently used in primary care in our country. In our 
study, we want to evaluate the effectiveness of honey at the 
recommended dose of 30 g three times a day in the adult 
population, since their benefit has only been explored in 
paediatrics. Unlike most published studies, these treat-
ments will be recommended for a maximum of 14 days, 
because as discussed earlier the average duration of symp-
toms with cough due to acute bronchitis is 3 weeks.
objECtIvEs
The main aim of the trial is to evaluate the clinical effec-
tiveness of adding three symptomatic treatments (dextro-
methorphan, ipratropium bromide or honey) to usual 
care in reducing days with moderate-to-severe cough 
compared with usual care. The secondary objectives are 
aimed at evaluating the clinical effectiveness of adding 
three symptomatic treatments to usual care compared with 
usual care in the reduction of days: (1) with cough, (2) 
with moderate-to-severe daytime cough, (3) with moder-
ate-to-severe nocturnal cough, (4) severe or moderate 
symptoms, (5) severe symptoms, (6) until the complete 
resolution of symptoms, (7) according to the baseline 
degree of bronchial hyper-reactiveness measured with 
peak-flow and also (8) to evaluate the utilisation of anti-
biotics and different symptomatic treatments in the four 
arms, (9) to evaluate the number of days of absence from 
work in the four study arms, (10) to assess the number 
of times patients re-attend for symptoms related to the 
episode of acute bronchitis, (11) to assess the number of 
complications related to the episode of acute bronchitis, 
(12) to assess patient satisfaction in the four study arms 
and (13) to assess the number of adverse events in the 
four study arms.
MEthods And AnAlysIs
trial design
This study is a phase IV, multicentre, pragmatic, parallel 
group, open randomised trial.
study arms
Once the patients are included in the trial, they will be 
randomised into one of the four treatment groups: (1) 
usual clinical practice group, (2) usual clinical prac-
tice +dextromethorphan (15 mg unit), one 15 mg tablet 
three times a day up to a maximum of 14 days, (3) usual 
clinical practice +ipratropium bromide (20 µg each puff), 
two puffs three times a day up to a maximum of 14 days, 
and (4) usual clinical practice +30 g of honey (one table-
spoon) three times a day up to a maximum of 14 days, two 
750 mg bottles of wildflower honey (the most frequent 
type of honey used in our country) will be provided and 
patients will be recommended to add the honey to a cup 
of lemon or thyme juice, milk herbal tea, yoghourt, herbal 
teas, etc. All the drugs and products used in this study are 
already marketed, and therefore, the manufacturers are 
responsible for the elaboration and control of samples. 
The study drugs will be provided free to the participants 
by the sponsor. The provision, secondary conditioning 
and distribution of the study drugs and products will 
be performed by the Barcelona primary care pharmacy 
service. All the study drugs as well as the honey will be 
kept at room temperature. To improve compliance, 
participants will be asked to record their daily dosage in 
the symptom diary.
sample size
For the sample size calculation, a recent publication 
about delayed antibiotic prescribing carried out in Spain 
using the same symptom diaries with specific data from 
the group of patients with acute bronchitis has been 
considered, from which an average duration of 5.5 days 
of moderate-to-severe cough was obtained, with a SD of 
4.5 days.35 Considering a reduction of 1.5 days as a clin-
ically relevant outcome, a sample of 167 patients per 
group is estimated (a total of 668). The power to detect 
the difference was assumed to be 0.8, with a two-sided 
significance level of 0.05. The allocation ratio of subjects 
into the groups is 1:1:1:1. We expect a 15% of loss to 
follow-up. Calculations have been performed with the aid 
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of GRANMO software, V.7.12 April 2012 (https://www. 
imim. cat/ ofertadeserveis/ software- public/ granmo/).
recruitment
The trial will be conducted in different primary care 
centres in Catalonia, Spain. A large geographical area of 
practices throughout Catalonia will be invited to partic-
ipate to maximise the generalisability of the sample 
of adults with uncomplicated acute bronchitis and to 
avoid saturation of research studies in some practices. 
The recruiting GPs will commence the study in January 
2019 and will attempt to recruit all eligible patients until 
October 2020. Provided the necessary sample is met 
before this date, the recruitment period will end at the 
time of the inclusion of the last patient. The sponsor 
reserves the right to prematurely discontinue this trial 
at any time in case (1) the expected inclusion objectives 
are not met or (2) new information appears regarding 
the efficacy or safety of any of the study medications that 
could significantly affect the continuation of the trial or 
overrules the previous positive evaluation of the bene-
fit-risk ratio.
Participants
Inclusion criteria
Potential participants who meet the following criteria 
will be included in this trial: (1) age 18 years or older, 
(2) symptoms of acute bronchitis, defined as an acute 
lower-respiratory-tract infection with cough as the 
predominant symptom, starting within 3 weeks before 
study inclusion, (3) patients who score ≥4 in either the 
daytime and/or nocturnal cough on a 7-point Likert scale 
and (4) patients who consent to participate.
Exclusion criteria
Patients with any of the following criteria will be excluded 
from this trial: (1) suspected pneumonia; if the profes-
sional suspects pneumonia, a chest X-ray will be recom-
mended and the patient will be randomised if this 
diagnosis is discarded, (2) criteria for hospital admission 
(impaired consciousness, respiratory rate >30 breaths/
min, pulse >125 beats/min, systolic blood pres-
sure <90 mm Hg or diastolic blood pressure <60 mm Hg, 
temperature >40°C or oxygen saturation <92%), (3) preg-
nancy or breast feeding, (4) baseline respiratory disease 
such as chronic obstructive pulmonary disease, asthma, 
tuberculosis or bronchiectasis, (5) associated significant 
comorbidity, such as moderate-to-severe heart failure, 
dementia, acute myocardial infarction/recent cerebral 
vascular accident (<3 months), severe liver failure, severe 
renal failure, (6) immunosuppression, such as chronic 
infection by HIV, transplanted, neutropenic, or patients 
receiving immunosuppressive treatment, (7) active 
neoplasm, (8) terminal illness, (9) history of intolerance 
or allergy to any of the study treatments, (10) patients 
in whom, in the opinion of the investigator, treatment 
with dextromethorphan, ipratropium bromide or honey 
is contraindicated, (11) patients living in long-term 
institutions and (12) difficulty in conducting scheduled 
follow-up visits.
Following the usual clinical practice, participating GPs 
may prescribe the concomitant therapy they consider 
appropriate, including analgesics such as NSAIDs or 
paracetamol, mucolytics, expectorants, antihistamines 
and also antibiotics. However, they will not be allowed to 
prescribe antitussives, including codeine, anticholinergic 
inhalers and they will not be allowed to recommend the 
use of honey, including honey candies, tablets or infu-
sions with honey. All drug information (name of product, 
purpose of administration, dosage, duration of adminis-
tration, etc) will be recorded on the patient case report 
form (CRF) and patients will fill out any other treatment 
they obtain or purchase from the pharmacy in their 
symptom diaries.
randomisation
Patients will be assigned sequentially as they enter the 
study. Randomisation of patients will be performed by 
registering the patient in an electronic CRF during the 
index visit. Patients will be stratified based on the previous 
duration of symptoms (≤1 week, >1 week). Once a patient 
is included in the trial and the randomisation has been 
centrally made, the investigator will provide the assigned 
treatment and record the dispensing and medication 
code in the electronic CRF. Since this is a multicentre 
study, a block procedure will be performed to assign 
patients to each of the health centres at a 1:1:1:1 ratio.
blinding
This is an open study. Neither physicians nor patients will 
be blind to the patient's assignment to the study group. 
The open nature of the clinical trial ensures that the 
results obtained in this study are very close to the reality 
of primary care, considering that both the participating 
GPs and the patients with uncomplicated acute bron-
chitis will be aware of the treatment given. However, the 
main outcome will be assessed by the patients themselves.
outcome measures
Primary outcome
Duration (days) of moderate-to-severe cough in days. 
Each symptom will be scored by the patient on a 7-point 
Likert scale (0 = not affected, 1 = very little problem, 
2 = slight problem, 3 = moderately bad, 4 = bad, 
5 = very bad, 6 = as bad as it could be). The number of days 
until the last day the patient scores 3 in either daytime 
cough or nocturnal cough in the paper-based symptom 
diary will be considered for the main outcome. We will 
use validated questionnaires, which have also been used 
in a previous study.36
Secondary outcomes
Different secondary outcomes will be taken into account: 
(1) duration of symptoms (number of days until the last 
day the patient scores 2 in any of the symptoms), (2) 
duration of moderate-to-severe daytime cough (number 
of days until the last day the patient scores 3 in daytime 
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cough), (3) duration of moderate-to-severe nocturnal 
cough (number of days until the last day the patient 
scores 3 in nocturnal cough), (4) duration of cough 
(number of days until the last day the patient scores 2 
in either daytime or nocturnal cough), (5) duration of 
severe symptoms (number of days until the last day the 
patient scores 5 in any of the symptoms), (6) duration of 
moderate-to-severe symptoms (number of days until the 
last day the patient scores 3 in any of the symptoms), (7) 
duration of moderate-to-severe cough in days according 
to the basal degree of bronchial hyper-reactiveness at the 
baseline visit, measured with peak flow (the greatest of 
three determinations will be considered), (8) utilisation 
of antibiotics and other symptomatic therapies within the 
first 4 weeks, (9) duration of work or school absenteeism 
due to the episode of acute bronchitis, (10) number of 
re-attendances to any doctor regarding the episode of 
acute bronchitis within the first 4 weeks, (11) number 
of complications related to the episode of acute bron-
chitis within the first 4 weeks, such as pneumonias, visits 
to emergency departments, hospital admissions, (12) 
patient satisfaction and (13) adverse reactions.
Withdrawal
Patients will be free to withdraw from the study at any 
time for any reason without prejudice to future care, and 
with no obligation to provide the reason for withdrawal. 
In addition, the investigator may withdraw a participant 
from the trial at any time if deemed necessary by any of 
the following reasons: (1) intercurrent process or illness 
that in the opinion of the investigator requires the with-
drawal of the patient's treatment, (2) the presence of an 
adverse event that requires the withdrawal of the patient’s 
treatment, (3) those who require a concomitant treat-
ment not allowed during study participation (antitussives, 
anticholinergic inhalers, honey) or (4) protocol violation.
During the trial, patients will be asked to inform about 
any signs of worsening symptoms, and investigators will 
evaluate appropriate measures if they need additional 
therapy. Since this is a pragmatic trial, patients who 
decide interrupting the study drug treatment but want to 
continue with the study procedures, will be followed in 
the same way as the other patients.
data management and monitoring
The investigators will follow the standard operating 
procedures of the trial for better quality of assessment and 
outcome data collection. The investigators who evaluate 
outcome measures should be restricted to only those GPs 
who have attended the training meetings. All assessment 
data and case reports will be collected at baseline (day 
1) and at the various follow-up visits in the intervention 
arms and control group. Collected documents and data 
will be managed by electronic CRF. Only the principal 
investigator or those who have permission will be able to 
access the data. The CRFs and other documents will be 
stored at a separate and secure location for 25 years after 
trial completion. Multicentre clinical trial monitoring will 
be conducted via periodic on-site/online visits, and all 
the patients recruited will be monitored following a risk 
approach monitoring plan.
Ascertainment of visits
The patients will be randomised to one of the four treat-
ment strategies. To standardise data collection, all of the 
participating GPs will be trained by the coordinating 
centre. The patients will receive information on the 
study by the participating GPs, and if they are interested 
in participating, they will be provided with an informed 
consent form to read and sign. A maximum length of 
10 to 15 min is expected for the interview, randomisation 
and the introduction of the data. The participating GPs 
will explain the study scheme and the visit programme 
to the patient (table 1). After randomisation, informa-
tion on the strategy to which they have been allocated 
will be given to the participants, and they will be given 
the free study medication and will be informed as to the 
appropriate measures to take in case of worsening or no 
improvement of their condition. In addition, they will 
be given a paper-based diary to be completed by them-
selves on a daily basis. The information collected in the 
diary includes: times in which study medication is taken, 
concomitant treatments used and a questionnaire of 
symptoms, which has been previously used in other 
studies.35 Patients will complete the diary while symptoms 
related to the respiratory condition are present.
GPs will call patients 2 to 3 days after their inclusion in 
the study to monitor their progress and resolve possible 
doubts regarding the completion of the diary. Patients 
will be scheduled for a second visit at day 15 (2 weeks after 
the patient inclusion) to evaluate their clinical evolu-
tion. Depending on the patient’s clinical evolution, the 
follow-up will be different: (1) clinical cure, defined as 
absence of symptoms; the diary will be collected and they 
will be called 2 weeks later to check if they have sought 
medical advice again due to the episode of acute bron-
chitis, (2) clinical improvement, defined as the persistence 
of symptoms but with improvement with respect to the 
index visit. Patients will be given a new symptom diary to 
be completed in the following 14 days and will be asked to 
return at day 29 to evaluate their condition. Participating 
GPs may prescribe any of the medications allowed by the 
study protocol, the same treatment as that which was previ-
ously received by the patient, or nothing if not necessary. 
If the doctor deems it necessary to prescribe any of the 
therapies under study (with the exception of the arm in 
which the patient is located), the patient will discontinue 
the trial and follow the usual clinical practice, (3) failure, 
when the patient is worse or presents the same symptoms 
as those presented at the index visit; patients will be with-
drawn from the study and will be managed according to 
the clinician’s best judgement. At day 29, patients who 
improved at day 15 will be similarly categorised as (1) 
clinical cure, (2) improvement or (3) failure. Patients 
with clinical cure or improvement will be contacted again 
at day 43 (6 weeks after the baseline visit) to record if they 
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have consulted with a professional regarding the episode 
of cough and to assess safety (figure 1).
statistical analysis
The characteristics of the study population will be 
described using frequencies for categorical variables 
and mean and SD for quantitative variables. To compare 
the different strategies with the usual treatment, we will 
use the chi-square tests for categorical variables and the 
Student t-test and variance analysis for continuous vari-
ables. Effectiveness evaluation will be primarily based 
on intention-to-treat (ITT) analysis in such a way that 
any event in any patient will be included in the group to 
which the patient was randomised, and per protocol (PP) 
Figure 1 Study scheme. GPs, general practitioners .
Table 1 Timetable of study period
Day Day 1 Day 2 to 4 Day 15 Day 29* Day 43†
Visit Visit 1 Phone visit 1 Visit 2 Visit 3 Phone visit 2 Phone visit 3
Visit at the centre X X X‡
Medical history and physical examination X
Explanation of the study and informed consent X
Initial CRF X
Randomisation X
Dispensing the study treatment X
Peak flow determination X
Giving out of the first symptom diary, up to day 15 X
Assessment of the clinical outcome X X X X X
Adherence to the study drug X X
Evaluation of adverse events X X X X X
Collection of the first symptom diary and giving out of the 
second symptom diary from day 16 to day 29§
X
Collection of the second symptom diary X
Evaluation of re-attendance to healthcare services due to 
infectious condition
X X X X X
Evaluation of complications X X X X X
*Final visit if the symptoms have disappeared.
†Only if the visit at day 29 is at the centre and a cure or improvement is recorded.
‡Phone visit if a cure is recorded at day 15.
§Only if the patient still has symptoms of infection (improvement).
CRF, case report form. 
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analysis will be used as a secondary analysis. ITT analysis 
will be conducted in all subjects randomised, and PP anal-
ysis will be conducted in those who complete the entire 
trial without violating the protocol.
To avoid the effect of potential confounders, the 
effectiveness of each treatment with respect to the 
usual clinical practice will be analysed through Cox 
proportional risk survival analysis, reporting both 
crude and adjusted relative risk. The effect of the treat-
ment will be adjusted for variables collected at baseline, 
such as age, gender, ethnicity, smoking status, alcohol 
consumption, peak-flow measurement, previous treat-
ment, previous vaccination, comorbidity and previous 
number of acute bronchitis.
Censoring and missing data: Those who discontinue, 
miss follow-up or, for whatever reason, are not evaluated 
for the main variable will be considered censored at the 
last follow-up date. In addition, patients who do not show 
symptoms of improvement along the study will also be 
censored at the last day of follow-up. We do not plan to 
make imputation of missing data.
Sub-analysis: To assess the consistency of the data 
collected by telephone (in subjects not attending the visit 
of the 15th and 29th), a sub-analysis will be carried out 
using only the data from the diary. A sub-analysis with the 
patients taking antibiotics will also be studied.
All the analyses will be done with the statistical software 
R (V.3.2 or higher) and the level of significance will be 
0.05.
Patient and public involvement
Patients and the public are not actively involved in the 
process of this study. However, the participants will be 
informed of the study results at the end of the trial.
EthICs And dIssEMInAtIon
Ethical issues
The trial will be conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice 
guidelines and Consolidated Standards of Reporting 
Trials guidelines. If the protocol needs relevant modi-
fications, the investigators are required to inform the 
institutional review board (IDIAP Jordi Gol, Barce-
lona, Spain) and the Spanish Agency of Medicines and 
Healthcare Products as well as participants and receive 
reapproval. Before the trial, investigators are required 
to provide all information related to the clinical trial 
to every patient, including the possible benefits and 
harms, other therapeutic choices and right to withdraw, 
via a written consent form approved by the institutional 
review board. After being provided with enough time 
and opportunity to ask questions and decide whether 
or not to participate, written informed consent will 
be obtained from all participants before study inclu-
sion. Data confidentiality will be ensured at all times, 
as stated in the researcher's commitment sheet, as will 
compliance with the current legislation regarding the 
protection of personal data. This is a clinical trial based 
on the outpatient setting, and neither patients nor 
researchers will receive any monetary compensation.
Adverse events and serious adverse events
This is a low intervention clinical trial meaning that the 
drugs administered are used in accordance with the 
terms of the marketing authorisation with a well-known 
safety profile and that the intervention on the patient 
poses no additional risk to the subject compared with 
usual clinical practice. The study medications used in this 
clinical trial have been widely prescribed and consumed 
for a long time, and the safety profile of these drugs is 
well-documented.
Adverse events will be recorded and followed if they are 
found to be serious or/and related to the study drug. The 
occurrence of this kind of adverse events will be moni-
tored. The rest of the adverse events will be treated as 
they are during the normal clinical practice, but will not 
be collected in the CRF.
dissemination
A range of dissemination activities are planned at 
national and international conferences. At the end of 
the trial, we will publish the final report in an open 
access peer-review journal even in the case of negative 
results, and the study results will also be disseminated 
via conference presentations. A summary of the findings 
will be sent to the participating practices on completion 
of the acute bronchitis 4 treatments (AB4T) study, and 
the participants will also be informed of the results.
dIsCussIon
Acute bronchitis is the most common respiratory tract 
infection seen in outpatient departments as approx-
imately 5% of the general population develop this 
infectious condition. Despite problems associated with 
antibiotic overuse in Western countries and the substan-
tial economic burden associated with acute bronchitis, 
currently no definitive medication is recommended. 
There are many studies exploring the efficacy of symp-
tomatic therapies, but different systematic reviews eval-
uating the effectiveness of antitussives, bronchodilators, 
herbs and natural remedies found that there was insuf-
ficient evidence to support the use of these treatments 
because of the high risk of bias, small sample sizes and the 
heterogeneity of the patients included in these studies 
as many of these patients had an infection other than 
acute bronchitis. This study is a multicentre, pragmatic, 
parallel group, open randomised placebo-controlled 
trial to evaluate the efficacy and safety of usual care plus 
three different symptomatic treatments that are widely 
consumed by patients with acute cough due to an uncom-
plicated lower respiratory tract infection in a rigorous 
and adequately powered study.
There are some limitations to this protocol. A micro-
biological study is not carried out, but since nearly 90% 
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of the episodes of acute bronchitis are of viral aetiology, 
treatment with antibiotics is not indicated and the micro-
biological study is therefore not necessary, similar to the 
usual practice in primary care, in which this procedure is 
not routinely performed. In addition, the study is prag-
matic and replicates current primary care. It is an open 
and unblinded study, in which doctors and patients will 
know the randomised study treatment assigned. The main 
objective of this study, as well as some of the secondary 
objectives are based on information provided by the 
patients themselves in the symptom diaries. However, at 
the baseline visit, GPs will be encouraged to explain how 
to fill in the diaries and will supervise how patients register 
the symptom diary. They will ask patients to return them 
at the various follow-up visits (days 15 and 29). We have 
previously found that the diary return rate is greater if we 
make patients come to follow-up visits. Notwithstanding, 
in the case of patients not returning the diaries, the 
doctor will contact them by phone to complete a short 
form in which the main study variables will be collected, 
in an attempt to minimise the number of losses.
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